0.80Open0.80Pre Close0 Volume1 Open Interest25.00Strike Price0.00Turnover135.78%IV28.17%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier15DDays to Expiry0.80Extrinsic Value100Contract SizeAmericanOptions Type0.2661Delta0.0580Gamma25.16Leverage Ratio-0.0603Theta0.0020Rho6.70Eff Leverage0.0137Vega
IDEAYA Biosciences Stock Discussion
Major FDA Breakthrough: IDEAYA's Eye-Saving Cancer Drug Advances to Phase 3 Trial
Breakthrough: First-in-Class Cancer Drug Combination Shows Promise in Bladder Cancer Study
Breakthrough Cancer Treatment: IDEAYA's IDE275 Targets Major Tumor Types with GSK Backing
Major Clinical Trial Update: IDEAYA's Novel Cancer Drug Targets 48,000 Annual NSCLC Cases
IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen
The agreement grants IDEAYA an option for an exclusive worldwide license from Biocytogen for a potential first-in-class B7H3/PTK7 topo-I-payload BsADC program. B7H3/PTK7 has been found to be co-expressed in multiple solid tumor types, including double-digit percent prevalence in...
📊⚡️📊
No comment yet